Endometriosis - Drug Pipeline Landscape, 2023
Description
Endometriosis - Drug Pipeline Landscape, 2023
Endometriosis is a disorder in which tissues similar to, but not the same as, the lining of the uterus are found elsewhere in the body. The lining of your uterus is called the endometrium. Endometriosis occurs when endometrial-like tissue grows on your ovaries, bowel, and tissues lining your pelvis.
The exact cause of endometriosis unknown. Explanations of possibility include retrograde menstruation, transformation of embryonic cell, transformation of peritoneal cells, surgical scar implantation and endometrial cell transport.
Endometriosis patients may have symptoms of menstrual cramps, abdominal pain or back pain, infertility, painful bowel movements, vaginal bleeding, pain with intercourse and other signs and symptoms include fatigue, diarrhea, constipation, bloating or nausea.
Diagnosis of endometriosis includes pelvic exam, ultrasound, magnetic resonance imaging and laparoscopy.
Treatment of endometriosis include medication or surgery. Therapies used to treat endometriosis include hormonal contraceptives, gonadotropin-releasing hormone (Gn-RH) agonists and antagonists, progestin therapy and aromatase inhibitors. Surgical options include laparoscopy and hysterectomy.
The companies active in the development of endometriosis drugs are Aptorum., Bayer AG, Chugai Pharmaceutical, Ferring Pharmaceuticals etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Endometriosis treatment such as DLBS1442, HMI-115, OBE2109 and others. Key players involved in the development of therapies to treat Endometriosis are Dexa Medica Group, Enteris BioPharma Inc, Hope Medicine (Nanjing) Co Ltd, Mitsubishi Tanabe Pharma Development America Inc, ObsEva SA and others. Two drugs are under late-stage Phase III clinical trials and ten drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Endometriosis - Drug Pipeline Landscape, 2023 report provides an overview of the Endometriosis pipeline drugs. This report covers detailed insights on Endometriosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Endometriosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Endometriosis is a disorder in which tissues similar to, but not the same as, the lining of the uterus are found elsewhere in the body. The lining of your uterus is called the endometrium. Endometriosis occurs when endometrial-like tissue grows on your ovaries, bowel, and tissues lining your pelvis.
The exact cause of endometriosis unknown. Explanations of possibility include retrograde menstruation, transformation of embryonic cell, transformation of peritoneal cells, surgical scar implantation and endometrial cell transport.
Endometriosis patients may have symptoms of menstrual cramps, abdominal pain or back pain, infertility, painful bowel movements, vaginal bleeding, pain with intercourse and other signs and symptoms include fatigue, diarrhea, constipation, bloating or nausea.
Diagnosis of endometriosis includes pelvic exam, ultrasound, magnetic resonance imaging and laparoscopy.
Treatment of endometriosis include medication or surgery. Therapies used to treat endometriosis include hormonal contraceptives, gonadotropin-releasing hormone (Gn-RH) agonists and antagonists, progestin therapy and aromatase inhibitors. Surgical options include laparoscopy and hysterectomy.
The companies active in the development of endometriosis drugs are Aptorum., Bayer AG, Chugai Pharmaceutical, Ferring Pharmaceuticals etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Endometriosis treatment such as DLBS1442, HMI-115, OBE2109 and others. Key players involved in the development of therapies to treat Endometriosis are Dexa Medica Group, Enteris BioPharma Inc, Hope Medicine (Nanjing) Co Ltd, Mitsubishi Tanabe Pharma Development America Inc, ObsEva SA and others. Two drugs are under late-stage Phase III clinical trials and ten drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Endometriosis - Drug Pipeline Landscape, 2023 report provides an overview of the Endometriosis pipeline drugs. This report covers detailed insights on Endometriosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Endometriosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
105 Pages
- 1. Introduction
- 1.1 Endometriosis - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Endometriosis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Endometriosis - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.1.1 DLBS1442
- 5.1.2 OBE2109
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 HMI-115
- 5.2.2 KLH-2109
- 5.2.3 Leuprolide
- 5.2.4 MT-2990
- 5.2.5 NA-0116
- 5.2.6 NS-580
- 5.2.7 Quinagolide
- 5.2.8 SHR7280
- 5.2.9 TU2670
- 5.2.10 VML-0501
- 5.3 Clinical Stage Drugs - Phase I
- 5.3.1 AMY109
- 5.3.2 BAY 2599210
- 5.3.3 BAY2328065
- 5.3.4 FOR-6219
- 5.4 Clinical Stage Drugs - Preclinical
- 5.4.1 BOL-DP-o-08
- 5.4.2 Goserelin
- 5.4.3 IW-3300
- 5.4.4 NLS-1
- 5.4.5 TTX 334E
- 5.4.6 VAL301
- 5.5 Clinical Stage Drugs - Discovery
- 5.5.1 Endometriosis Project
- 5.5.2 Endometriosis Drug
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Aptorum Group Ltd
- 9.2 Bayer
- 9.3 Breath of Life International Pharma Ltd
- 9.4 Celmatix
- 9.5 Chugai Pharmaceutical
- 9.6 Dexa Medica Group
- 9.7 Enteris BioPharma Inc
- 9.8 Ferring Pharmaceuticals
- 9.9 Forendo Pharma Ltd
- 9.10 Hope Medicine (Nanjing) Co Ltd
- 9.11 Ironwood Pharmaceuticals Inc
- 9.12 Jiangsu HengRui Medicine Co Ltd
- 9.13 Kissei Pharmaceutical Co Ltd
- 9.14 Mithra Pharmaceuticals SA
- 9.15 Mitsubishi Tanabe Pharma Development America Inc
- 9.16 Navad Life Sciences Pte Ltd
- 9.17 Nippon Shinyaku
- 9.18 ObsEva SA
- 9.19 Pharmiva AB
- 9.20 Temple therapeutics
- 9.21 TiumBio Co Ltd
- 9.22 Valirx Plc
- 9.23 Viramal Limited
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – OBE2109/ObsEva SA
- Table 2.2 Clinical Trial Details – DLBS1442/Dexa Medica Group
- Table 2.3 Clinical Trial Details – OBE2109/ObsEva SA
- Table 2.4 Clinical Trial Details – HMI-115/Hope Medicine (Nanjing) Co Ltd
- Table 2.5 Clinical Trial Details – KLH-2109/Kissei Pharmaceutical Co Ltd
- Table 2.6 Clinical Trial Details – Leuprolide/Enteris BioPharma Inc
- Table 2.7 Clinical Trial Details – MT-2990/Mitsubishi Tanabe Pharma Development America Inc
- Table 2.8 Clinical Trial Details – NS-580/Nippon Shinyaku
- Table 2.9 Clinical Trial Details – Quinagolide/Ferring Pharmaceuticals
- Table 2.10 Clinical Trial Details – SHR7280/Jiangsu HengRui Medicine Co Ltd
- Table 2.11 Clinical Trial Details – TU2670 /TiumBio Co Ltd
- Table 2.12 Clinical Trial Details – VML-0501/Viramal Limited
- Table 2.13 Clinical Trial Details – AMY109/Chugai Pharmaceutical
- Table 2.14 Clinical Trial Details – BAY2328065/Bayer
- Table 2.15 Clinical Trial Details – FOR-6219/Forendo Pharma Ltd
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Endometriosis, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Endometriosis, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Endometriosis, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Endometriosis, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Endometriosis, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
